Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Introduction: By depleting autoreactive B cells, CD19-targeted CAR-T have shown early yet promising efficacy in treating patients with B cell-driven autoimmune diseases. However, the clinical ...

Title: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases • Results: ATG-201 ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.16%, which has investors questioning if this is right time to ...

The two lead cancer programs are CB-010, a CD19-targeting cell therapy in development for B cell non-Hodgkin lymphoma, and CB-011, a BCMA-targeting cell therapy in development for multiple myeloma.

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

Intellia Therapeutics, Inc.’s NTLA share price has surged by 5.05%, which has investors questioning if this is right time to ...